Last reviewed · How we verify
Fleet
Fleet, marketed by Norgine, holds a position in the pharmaceutical market with its key composition patent expiring in 2028. The drug's primary strength lies in its established market presence and regulatory approval. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | Fleet |
|---|---|
| Also known as | Sodium Phosphate |
| Sponsor | Norgine |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Non-inferiority RCT on Fish Waste-Derived vs. Synthetic Vitamin D Supplementation in Healthy Adults With Suboptimal Vitamin D Levels (NA)
- Bowel Preparation in Minimally Invasive Gynecologic Surgery (NA)
- " Fume Events in Air Flights: Consequences on Cabin Air Quality and on Aircrews Health of a French Fleet of Aircraft"
- TES RCT Fleet Enema vs Oral Mechanical Bowel Prep (PHASE4)
- Mindfulness and Chronic Low Back Pain (NA)
- A Trial of Three Types of Enemas Used to Treat Functional Constipation in Children (NA)
- Chronic Low Back Pain and Meditation (EARLY_PHASE1)
- Microbiota Modification for the Treatment of Motor Complication of Parkinson´s Disease (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fleet CI brief — competitive landscape report
- Fleet updates RSS · CI watch RSS
- Norgine portfolio CI